FindTrial
Sign In

Definitive Surgery

PROCEDURE3 trials

Sponsors

Leo W. Jenkins Cancer Center, Peking University People's Hospital, Okayama University

Conditions

BRCA MutationBRCA-Associated Breast CarcinomaBRCA1 MutationBRCA2 MutationBreast CancerBreast NeoplasmsOsteosarcoma of PelvisTriple Negative Breast Cancer

Phase 2

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
TerminatedNCT00542191
Leo W. Jenkins Cancer CenterBreast Cancer
Start: 2007-07-31End: 2016-08-02Updated: 2021-05-26
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
RecruitingNCT05485766
Okayama UniversityBRCA1 Mutation, BRCA2 Mutation, BRCA-Associated Breast Carcinoma +5
Start: 2024-07-16End: 2028-09-30Target: 23Updated: 2025-03-20

Unknown Phase

Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum
NCT03360760
Peking University People's HospitalOsteosarcoma of Pelvis
Start: 2018-08-01End: 2025-02-28Target: 100Updated: 2018-08-28

Related Papers

OPERETTA: A phase II study evaluating neoadjuvant and adjuvant olaparib plus pembrolizumab following platinum-based chemotherapy plus pembrolizumab for germline BRCA mutated triple negative breast cancer.
Journal of Clinical Oncology2025-05-28
Pretreatment neutrophil to lymphocyte ratio (NLR) in patients with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy.
Journal of Clinical Oncology2016-05-205 citations
Neoadjuvant metronomic chemotherapy in triple-negative breast cancer (TNBC) (NCT00542191): Updated results from a phase II trial.
Journal of Clinical Oncology2016-05-204 citations